Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The endothelium-derived hyperpolarizing factor (EDHF) pathway refers to a group of mechanisms and/or substances produced by the vascular endothelium that cause hyperpolarization and relaxation of underlying vascular smooth muscle cells, leading to vasodilation. It plays a critical role in regulating organ blood flow, peripheral vascular resistance, and blood pressure, especially in smaller vessels and when NO production is compromised. EDHF-mediated responses involve diffusible factors (e.g., potassium ions, epoxyeicosatrienoic acids, hydrogen peroxide) and/or direct electrical coupling via myoendothelial gap junctions. Dysfunction in this pathway is linked to cardiovascular diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endothelium-derived hyperpolarizing factor pathway (None).